Mayo Clinic Speakers at AABB Annual Meeting & CTTXPO 2012

The Mayo Clinic Department of Laboratory Medicine and Pathology will have multiple moderators, speakers and poster presentations at this year’s AABB Annual Meeting & CTTXPO 2012, held Oct. 6-9 in Boston, Mass. For your reference, information about every Mayo Clinic speaker has been organized below (Mayo Clinic speakers are in italics).

AABB advances the practice and standards of transfusion medicine and cellular therapies to optimize patient and donor care and safety.

Title Gen X, Gen Y, Gen Z: Keeping Everyone Engaged in the Workplace
Date/Time Oct. 6, 2012 from 10:30 a.m.-noon
Director Karafa Badjie, MS, MLS(ASCP), SBB
Moderator Susan South, MAOM, MT(ASCP)SBB)
Level Intermediate
Intended Audience Physicians, Scientists, Technologists, Managers/Supervisors
Objectives
  • Discuss the concept of operational support teams as an infrastructure to engage, embed and empower employees in continuous process improvement and operational activities.
  • Discuss different strategies to create an operational environment that enhances professional growth, retention and succession planning.
Event Description Do you sometimes feel that techs today don't really care: care about patients, care about the profession, care about being involved in operational support activities; care about expanding their knowledge and opportunities for professional growth? Is this true, or is this a misperception, perhaps brought on by differences in generations? How do we keep techs interested, new techs with their twitter and Facebook, older techs with their been there, done that attitude? This workshop will focus on ideas to create an environment or infrastructure that maximizes the attitudes, skills, and knowledge of all staff, to allow them to fully engage, grow and contribute while in the workplace.
Speakers Steven Armstrong, MT(AMT), BB(ASCP)SBB, MSHA; Karafa Badjie, MS, MLS(ASCP), SBB; Theresa Downs, MT(ASCP)SBB, CQA(ASQ); Claudia Grabowski

 

Title Emerging Trends in Therapeutic Apheresis AABB/ASFA Joint Program
Date/Time Oct. 6, 2012 from 4:00 - 5:30 p.m.
Director/
Moderator
Jeffrey Winters, MD
Level Intermediate to Advanced
Intended Audience Physicians, Scientists, Technologists, Nurses
Objectives
  • Discuss the potential role for plasma exchange in the treatment of patients suffering from heparin induced thrombocytopenia (HIT) as well as the role for prophylactic plasma exchange in patients requiring heparin exposure.
  • Explain the difference between red cell exchange using isovolemic hemodilution and red cell exchange not using this technique and describe the indications for and advantages of isovolemic hemodilution in red cell exchange.
  • Describe the pathophysiology of idiopathic dilated cardiomyopathy and summarize the role of therapeutic apheresis in the treatment of this disorder.
Event Description Therapeutic apheresis can be used to treat a variety of disorders, most of which are uncommon. This session will discuss emerging treatments and disease indications for therapeutic apheresis. The first speaker will examine the potential role of plasma exchange in heparin induced thrombocytopenia (HIT), both as a therapeutic and a prophylactic treatment. The published literature will be objectively reviewed concerning its potential role. The second speaker will discuss a modification to the routine red cell exchange procedure used to treat sickle cell anemia. This modification offers advantages over the routine red cell exchange. This modification, its advantages, and indications will be reviewed. Finally, the third speaker will discuss the potential role of therapeutic apheresis in the treatment of idiopathic dilated cardiomyopathy and its potential to delay or avoid cardiac transplantation in this disorder. While not currently widely used in the United States, this treatment is accepted care in some European countries. The available treatment options and the evidence supporting its use will be summarized.
Speakers Elizabeth Jaben; Ravi Sarode, MD; Jeffrey Winters, MD

 

Title Effect of Increasing Hemoglobin Cutoff in Male Donors and Increasing Inter-Donation Intervals in Whole Blood Donors
Date/Time Oct. 6, 2012 from 4:00 - 5:30 p.m.
Director Manish Gandhi, MD 
Moderator Peter Tomasulo, MD
Level Intermediate to Advanced
Intended Audience Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs
Objectives
  • Review blood donor hemoglobin cutoff guidelines in developed countries.
  • Review the effect of frequent blood donations on body iron stores.
  • Evaluate the effect of increasing hemoglobin cutoff for whole blood in males and inter-donation intervals on United States blood supply.
Event Description The NHANES-III survey found hemoglobin concentrations >13.5 g/dL and >12.0 g/dL in normal Caucasian males and females. In the United States, hemoglobin >12.5 g/dL is required for blood donation, which allows "anemic" males to donate blood while excluding "normal" females. Low hemoglobin is the major cause of deferral in donors and deferrals are associated with decreased donor return rates. Additionally, frequent blood donations are associated with depletion of body iron stores. This session will review the higher hemoglobin cutoffs and inter-donation intervals in developed countries. Analysis of the effect of frequent blood donations on body iron stores will be reviewed. Analysis of the effect of various hemoglobin cutoffs and inter-donation intervals on an individual center's blood supply will be presented.
Speakers Manish Gandhi, MD; Jed Gorlin, MD; Joseph Kiss, MD

 

Title Managing Events in a Culture of Safety
Date/Time Oct. 7, 2012 from 8:30 - 10:00 a.m.
Director/
Moderator 
Valerie Halling, MLT(ASCP), MEd, BBSS(ASQ)
Level Intermediate
Intended Audience Technologists, Nurses, Managers/Supervisors, CEOs/CFOs
Objectives
  • Discuss the impact of event management in a culture of safety.
  • Describe how value stream mapping (VSM) was used to plan implementation of an electronic event management system.
  • Discuss the use and results of a survey developed to assess the current culture of event reporting.
  • Summarize opportunities for improvement in event management.
Event Description The goal of a commitment to safety is to establish a more open work environment built on shared understanding and clear expectations — one where hierarchies are leveled so staff can speak up regarding concerns, collectively learn from errors and respectfully work together to create a safer environment by eliminating preventable harm. How can you shift the paradigm of an event management system seen as somewhat punitive to a process that establishes a more open work environment? How do you build clear expectations of accountability, encourage self-reporting and focus on the process rather than personnel? How do you improve your current event management system and engage your staff? This presentation will address how value stream mapping and the voice of the customer can be used to identify and prioritize areas for improvement in an event management system.
Speakers Amjad Barhoush, MS, BB(ASCP)SBB, CQA(ASQ); Terri Coyle, MS, MT(ASCP), CLS(NCA); Valerie Halling, MLT(ASCP), MEd, BBSS(ASQ)

 

Title Stem Cells for Regenerative Repair:
Promise and Potential
Date/Time Oct. 7, 2012 from 2:00 - 3:30 p.m.
Director  Pampee Young, MD, PhD
Moderator Eapen Jacob, MD
Level Intermediate to Advanced
Intended Audience Scientists, Technologists, Nurses
Objectives
  • Review different types of stem cells currently utilized for regenerative therapy.
  • Assess mesenchymal stem cells in regenerative medicine and cardiovascular repair.
  • Evaluate the use of tissue-specific stem cells, i.e., cardiac stem cells.
  • Discuss recent information from clinical trials.
Event Description Heart disease remains the leading cause of morbidity and mortality in the developed world despite significant surgical and pharmacological advances in its treatment. The use of stem cells for cardiac repair
and/or cardiac regeneration in heart failure has been intensely studied for the past decade. While clinical trials using various stem cell sources for the treatment ventricular dysfunction and myocardial repair have demonstrated the safety of both allogeneic and autologous cells, the
functional results remain modest, suggesting that a good deal of work needs to be done to improve their therapeutic capacity. Learn the major hurdles remaining and progress to date, specifically with the novel cardiosphere/cardiac progenitor cell source.
Speakers Allan Dietz, PhD; Jan Kajstura, PhD; Pampee
Young, MD, PhD

 

Title The Art of Agreements: Understanding and Navigating the Complex World of Contracts, Agreements and Consents for the Legal Novice
Date/Time Oct. 9, 2012 from 8:30 - 10:00 a.m.
Director/
Moderator 
Doug Padley, MT(ASCP) 
Level Basic to Intermediate
Intended Audience Physicians, Scientists, Technologists, Managers/Supervisors, CEOs/CFOs
Objectives
  • Describe the various types of agreements commonly encountered in transfusion medicine and cellular therapy, including technical and quality agreements, scope of work documents with contractors, memoranda of understanding between two business entities, patient consents and business contracts.
  • Identify the key components of the various types of agreements, what to look for and how to avoid common pitfalls.
  • Provide best practices and practical advice on how to manage the many agreements required in the day-to-day business operations, focusing on how the relevant content of those agreements is made available to those who need to know.
Event Description Agreements of one type or another have direct impact on the work of transfusion medicine and cellular therapy professionals on a daily basis. The speakers in this session will discuss and provide examples or excerpts from commonly encountered agreements and other contract-like documents. Patient consent documents for participation in clinical research studies will be discussed with regard to how those consents affect day-to-day laboratory practices. Things to consider for business agreements such as non-disclosure or quality/technical agreements between entities will be discussed, specifically about how they drive day-to-day practice. Finally, real-life experiences with agreements in the form of best practices and lessons learned will be reviewed.
Speakers Kate Gallin Heffernan; Doug Padley, MT(ASCP)

 

Poster Presentations

Date Poster Presenter
Oct. 6, 2012 Staffing to Workload in the Component Laboratory Jesica Foster
Oct. 6, 2012 Blood Cell Analyzer Effect on Predicted Platelet Apheresis Kimberly Duffy
Oct. 6, 2012 Using Root Cause Analysis to Rebuild a Broken Competency Assessment Process Melissa Gillis
Oct. 6, 2012 Reagent Inventory Management in a Busy Immunohematology Reference Laboratory Georgette Benidt
Oct. 6, 2012 Bridging the Gap Between SOPs and Training Jody Wayne
Oct. 6, 2012 The Impact of Thawed Plasma Usage During Emergency Medical Helicopter Transport Karafa Badjie & Lisa Button
Oct. 6, 2012 Evaluating the Sysmex XE2100D Automated Hematology Analyzer Richard Emery
Oct. 6, 2012 Discarding Blood Due to Transport Time Ranee Wannarka-Farlinger
Oct. 6, 2012 Defining A Normal Range For Cold Agglutinin Titers Brenda Bendix
mayocliniclabs

Mayo Medical Laboratories

This post was authored by the Marketing Team at Mayo Medical Laboratories.